Back to AMGNView full pipeline
Phase 3
Development Phase
3
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Q3 '27
Q3 '27
Competitive Landscape
5 competitors in Small Cell Lung Cancer
View Full LandscapeDrug Information
Target Indication
Small Cell Lung Cancer
Mechanism of Action
BiTE (DLL3xCD3)
Clinical Trial
NCT05060016Last updated: 12/3/2025
Patent & Exclusivity
Regulatory Approvals
EMA5/29/2026
Imdylltra
Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Omitted Vincristine+Dexamethasone pulsesPhase 3
Leukemia, Acute Lymphoblastic
MetoprololPhase 3
Cardiovascular Disease
Etanercept LiquidPhase 3
Rheumatoid Arthritis
romosozumab HCP administration with PFSPhase 3
Post-Menopausal Osteoporosis
Inotuzumab Ozogamicin+Standard Maintenance TherapyPhase 3
Leukemia, Acute Lymphoblastic
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
